{
    "pmcid": "11211474",
    "qa_pairs": {
        "What advantage does the multivalent form of VHH60 offer according to the study?": [
            "Enhanced potency, particularly beneficial for vulnerable populations",
            "Reduced production costs and increased yield",
            "Improved solubility and stability in physiological conditions",
            "Broader cross-reactivity with other coronaviruses"
        ],
        "What is the origin of the nanobody VHH60 used to neutralize SARS-CoV-2?": [
            "It was engineered from the FDA-approved nanobody caplacizumab.",
            "It was derived from a llama immunized with SARS-CoV-2 antigens.",
            "It was synthesized de novo using computational design techniques.",
            "It was isolated from a human convalescent plasma sample."
        ],
        "What method was used to introduce amino acid diversity in the complementary determining regions of the nanobody library?": [
            "High-speed DNA mutagenesis",
            "CRISPR-Cas9 gene editing",
            "Random peptide synthesis",
            "Directed evolution"
        ],
        "What was the IC50 value of VHH60 in inhibiting viral infection in vitro?": [
            "1.87 nM",
            "3.45 nM",
            "0.95 nM",
            "2.75 nM"
        ],
        "Which specific residues on the SARS-CoV-2 receptor binding domain does VHH60 bind to?": [
            "S351, S470-471, S493-494",
            "S345, S460-461, S483-484",
            "S360, S475-476, S498-499",
            "S355, S465-466, S488-489"
        ]
    }
}